What is left of the endoscopic antireflux devices?

Current Opinion in Gastroenterology

Volumn 25, Issue 4, 2009, Pages 352-357

  Jafri, Syed Mohammed ^a,b   Arora, Gaurav ^a,b   Triadafilopoulos, George ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fundoplication; Gastroesophageal reflux; Injection; Radiofrequency ablation

Indexed keywords

PROTON PUMP INHIBITOR;

CLINICAL TRIAL; ENDOSCOPY; ESOPHAGITIS; ESOPHAGUS; ESOPHAGUS PERFORATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LOWER ESOPHAGUS SPHINCTER; PNEUMOPERITONEUM; QUALITY OF LIFE; RADIOFREQUENCY; RADIOFREQUENCY ABLATION; REVIEW; STOMACH FUNDOPLICATION; SURGICAL TECHNIQUE; SYMPTOM;

CATHETER ABLATION; ENDOSCOPES; ENDOSCOPY; EQUIPMENT SAFETY; ESOPHAGOGASTRIC JUNCTION; ESOPHAGOSCOPES; FEMALE; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; GASTROSCOPES; HUMANS; MALE; PATIENT SATISFACTION; PROGNOSIS; PROTON PUMP INHIBITORS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 68049091020     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32832ad8b4     Document Type: Review

References (42)

1. Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008; 103:267-275. (Pubitemid 351248746)
2. Moayyedi P, Axon AT. Review article: gastro-oesophageal reflux disease - the extent of the problem. Aliment Pharmacol Ther 2005; 22 (Suppl 1):11-19. (Pubitemid 41153075)
3. Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59:433-445.
4. Carlson MA, Frantzides CT. Complications and results of primary minimally invasive antireflux procedures: a review of 10 735 reported cases. J Am Coll Surg 2001; 193:428-439.
5. Hogan WJ. Clinical trials evaluating endoscopic GERD treatments: is it time for a moratorium on the clinical use of these procedures? Am J Gastroenterol 2006; 101:437-439.
6. Swain CP, Mills TN. An endoscopic sewing machine. Gastrointest Endosc 1986; 32:36-38.
7. Tam WC, Holloway RH, Dent J, et al. Impact of endoscopic suturing of the gastroesophageal junction on lower esophageal sphincter function and gastroesophageal reflux in patients with reflux disease. Am J Gastroenterol 2004; 99:195-202. (Pubitemid 38279856)
8. Liu JJ, Glickman JN, Li X, et al. Smooth muscle remodeling of the gastroesophageal junction after endoluminal gastroplication. Gastrointest Endosc 2007; 65:1023-1027. (Pubitemid 46770729)
9. Schiefke I, Zabel-Langhennig A, Neumann S, et al. Long term failure of endoscopic gastroplication (EndoCinch). Gut 2005; 54:752-758. (Pubitemid 40732086)
10. Kadirkamanathan SS, Yazaki E, Evans DF, et al. An ambulant porcine model of acid reflux used to evaluate endoscopic gastroplasty. Gut 1999; 44:782-788. (Pubitemid 29244212)
11. Wenzel G, Kuhlbusch R, Heise J, Frieling T. Relief of reflux symptoms after endoscopic gastroplication may be associated with reduced esophageal acid sensitivity: a pilot study. Endoscopy 2005; 37:236-239. (Pubitemid 40361100)
12. Hill LD, Kozarek RA, Kraemer SJ, et al. The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 1996; 44:541-547.
13. Lin BR, Wong JM, Chang MC, et al. Abnormal gastroesophageal flap valve is highly associated with gastroesophageal reflux disease among subjects undergoing routine endoscopy in Taiwan. J Gastroenterol Hepatol 2006; 21:556-562.
14. Schwartz MP, Wellink H, Gooszen HG, et al. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut 2007; 56:20-28. (Pubitemid 46044884)
15. Filipi CJ, Lehman GA, Rothstein RI, et al. Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial. Gastrointest Endosc 2001; 53:416-422.
16. Mahmood Z, McMahon BP, Arfin Q, et al. Endocinch therapy for gastrooesophageal reflux disease: a one year prospective follow up. Gut 2003; 52:34-39. (Pubitemid 36020761)
17. Thomson M, Fritscher-Ravens A, Hall S, et al. Endoluminal gastroplication in children with significant gastro-oesophageal reflux disease. Gut 2004; 53:1745-1750. (Pubitemid 39556890)
18. Abou-Rebyeh H, Hoepffner N, Rosch T, et al. Long-term failure of endoscopic suturing in the treatment of gastroesophageal reflux: a prospective follow-up study. Endoscopy 2005; 37:213-216. (Pubitemid 40361096)
19. Chen YK, Raijman I, Ben-Menachem T, et al. Long-term outcomes of endoluminal gastroplication: a U.S. multicenter trial. Gastrointest Endosc 2005; 61:659-667. (Pubitemid 40603032)
20. Thomson M, Antao B, Hall S, et al. Medium-term outcome of endoluminal gastroplication with the EndoCinch device in children. J Pediatr Gastroenterol Nutr 2008; 46:172-177. The authors examine the outcome of EndoCinch plication in children with GERD (6-16 years). Patients demonstrated improvement in symptoms and QoL. The study was limited by a small sample size (17 patients). Significant improvement in heartburn and reflux symptoms persisted at 3 years. Four of the 17 patients required a repeat procedure. (Pubitemid 351161123)
21. Mahmood Z, Byrne PJ, McMahon BP, et al. Comparison of transesophageal endoscopic plication (TEP) with laparoscopic Nissen fundoplication (LNF) in the treatment of uncomplicated reflux disease. Am J Gastroenterol 2006; 101:431-436. (Pubitemid 43340914)
22. Paulssen EJ, Lindsetmo RO. Long-term outcome of endoluminal gastroplication in the treatment of gastro-oesophageal reflux disease: effect of a second procedure. Scand J Gastroenterol 2008; 43:5-12. This study examined both long-term outcomes and emphasized the potential advantage of a second-look procedure using EndoCinch plication. Without a second procedure, medication use returned to baseline with significant loss of sutures. A second procedure in 20 of 119 patients helped keep these patients off medication over the long-term.
23. Ben-Menachem T, Goel S, Zonca M, et al. Endoscopic surveillance of plications after endoluminal gastroplication (ELPG) for GERD [abstract]. Gastrointest Endosc 2003; 57:AB128.
24. Mosler P, Aziz AM, Hieston K, et al. Evaluation of supplemental cautery during endoluminal gastroplication for the treatment of gastroesophageal reflux disease. Surg Endosc 2008; 22:2158-2163. This is the only clinical trial to examine the efficacy of supplementing sutures in endoscopic plication with heat cautery. In the small group (n = 18), patients randomized to cautery showed a trend toward improvement in heartburn and medication use; these trends were lost over the long term. Cautery did improve plication persistence, and studies in larger groups of patients may demonstrate efficacy.
25. Rothstein RI, Hynes ML, Grove MR, et al. Endoscopic gastric plication (EndoCinch) for GERD: a randomized, sham-controlled, blinded, singlecenter study [abstract]. Gastrointest Endosc 2004; 59:AB111.
26. Park PO, Hall-Angeras M, Ohlin B, et al. A prospective, multicenter, randomized, single-blind, parallel group study on the comparison between endoscopic cardia suturing and sham operation as a treatment of patients with gastroesophageal reflux symptoms [abstract]. Gastroenterology 2005; 128:A95.
27. Montgomery M, Hakanson B, Ljungqvist O, et al. Twelve months' follow-up after treatment with the EndoCinch endoscopic technique for gastrooesophageal reflux disease: a randomized, placebo-controlled study. Scand J Gastroenterol 2006; 41:1382-1389. (Pubitemid 44764399)
28. Cadiere GB, Rajan A, Rqibate M, et al. Endoluminal fundoplication (ELF): evolution of EsophyX, a new surgical device for transoral surgery. Minim Invasive Ther Allied Technol 2006; 15:348-355. (Pubitemid 46029437)
29. Cadiere GB, Rajan A, Germay O, Himpens J. Endoluminal fundoplication by a transoral device for the treatment of GERD: a feasibility study. Surg Endosc 2008; 22:333-342. This was the initial feasibility study for Esophyx plication in patients with chronic GERD. Adverse events included moderate abdominal pain. This study differed from many previous ones in allowing inclusion of patients with hiatal hernias. A trend toward improvement in GERD symptoms, PPI use and pH was demonstrated at 1 year.
30. Cadiere GB, Buset M, Muls V, et al. Antireflux transoral incisionless fundo-plication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 2008; 32:1676-1688. This largest study of Esophyx to date evaluated 86 patients. It revealed potential severe adverse events, including esophageal perforation and bleeding. This is weighed against improved QoL, reduced esophagitis, reduced PPI use and significant improvement in resting LES pressure.
31. Jobe BA, Koek GH, Kraemer SJ, et al. Tailored transoral incisionless fundoplication (TIF) in the treatment of GERD: the anatomic and physiologic basis for reconstruction of the esophagogastric junction using a novel approach [abstract]. Gastroenterology 2008; 134:A854. TIF performed on canine models in phase I and II trials demonstrated its anatomic impact. In canine models, TIF allowed for normalization of esophageal acid exposure, increased LES pressure and increased LES length over a 2-week period.
32. McMahon BP, Jobe BA, Kraemer SJ, et al. Use of the functional lumen imaging probe to determine structural changes in the region of the esophagogastric junction after endoluminal fundoplication using Esophyx for GERD [abstract]. Gastroenterology 2008; 134:A179. This animal, sham-controlled study using a quantitative functional lumen imaging probe did not find any difference in GEJ luminal diameter with the current TIF technique.
33. Yoo BM, Lehman GA, Triadafilopoulos G. Endoscopic treatments for GERD. In: Classen M, Tytgat GNJ, Lightdale C, editors. Gastroenterological endoscopy. 2nd ed. Stuttgart: Thieme; 2009.
34. Noar MD, Noar E. Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction. Surg Endosc 2008; 22:2440-2444. The authors demonstrated that RFA has the potential to correct gastroparesis in patients with concomitant reflux. At 6 months, 23 of 31 patients (74%) experienced normalization of gastric emptying. Four patients showed no improvement on their gastric emptying scan. There is no clear mechanism by which RFA corrects gastroparesis, although the authors postulate a reduction in transient LES relaxations.
35. Triadafilopoulos G. Changes in GERD symptom scores correlate with improvement in esophageal acid exposure after the Stretta procedure. Surg Endosc 2004; 18:1038-1044. (Pubitemid 38918011)
36. Triadafilopoulos G, Dibaise JK, Nostrant TT, et al. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD. Gastrointest Endosc 2001; 53:407-415. (Pubitemid 33586746)
37. Triadafilopoulos G, DiBaise JK, Nostrant TT, et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc 2002; 55:149-156. (Pubitemid 41115174)
38. Wolfsen HC, Richards WO. The Stretta procedure for the treatment of GERD: a registry of 558 patients. J Laparoendosc Adv Surg Tech A 2002; 12:395-402. (Pubitemid 36105955)
39. Arts J, Sifrim D, Rutgeerts P, et al. Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig Dis Sci 2007; 52:2170-2177. (Pubitemid 47246518)
40. Reymunde A, Santiago N. Long-term results of radiofrequency energy delivery for the treatment of GERD: sustained improvements in symptoms, quality of life, and drug use at 4-year follow-up. Gastrointest Endosc 2007; 65:361-366. (Pubitemid 46275633)
41. Corley DA, Katz P, Wo JM, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003; 125:668-676. (Pubitemid 37070685)
42. Comay D, Adam V, da Silveira EB, et al. The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis. Can J Gastroenterol 2008; 22:552-558. This Canadian study utilized a Markov model to determine the current 5-year costeffectiveness of laparoscopic Nissen fundoplication, the Stretta procedure and PPI therapy in the management of GERD. PPIs exhibited the lowest costs ($40 per symptom-free month) and the greatest efficacy in terms of symptom-free months, although not in quality-adjusted life years in which fundoplication was more effective but still more costly. The authors concluded that at the present cost, PPI therapy was most cost-effective.